BAM
SPRO icon

Belpointe Asset Management’s Spero Therapeutics SPRO Stock Holding History

Belpointe Asset Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,560
Closed -$7.89K – 3848
2022
Q4 		$7.89K Buy
+4,560
New +$8.51K ﹤0.01% 2735

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Belpointe Asset Management's SPRO Position: Q1 2023 in Review

Belpointe Asset Management sold out of Spero Therapeutics (SPRO) in Q1 2023, closing a stake of 4,560 shares — an estimated $7.89K sold.

Belpointe Asset Management first reported a position in SPRO in Q4 2022 and held it in 1 quarter. The position peaked at $7.89K in Q4 2022. 48 funds tracked by Wall St. Rank hold SPRO as of Q1 2023.

  • Belpointe Asset Management reported no remaining Spero Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 4,560 Spero Therapeutics shares in Q1 2023, an estimated $7.89K.
  • Belpointe Asset Management first reported a position in Spero Therapeutics in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's Spero Therapeutics position peaked at $7.89K in Q4 2022.
  • 48 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.